124 results
SC TO-I
EX-99
CYDY
CytoDyn Inc.
3 Jun 24
Issuer tender offer statement
5:10pm
business, financial condition, or reputation. In addition, publicity surrounding any investigation, even if ultimately resolved in our favor, could
424B3
CYDY
CytoDyn Inc.
16 Apr 24
Prospectus supplement
5:16pm
in the clinical development of leronlimab and is exploring potential business opportunities to continue the investigation of leronlimab for solid tumors
424B3
CYDY
CytoDyn Inc.
16 Apr 24
Prospectus supplement
5:15pm
in the clinical development of leronlimab and is exploring potential business opportunities to continue the investigation of leronlimab for solid tumors
424B3
kihoblua ni24
19 Jan 24
Prospectus supplement
5:15pm
424B3
5tnby8
24 Oct 23
Prospectus supplement
6:01am
424B3
gn3jyc27hlyij
10 Oct 23
Prospectus supplement
6:02pm
POS AM
qucm uhm6286a7acu0
2 Oct 23
Prospectus update (post-effective amendment)
5:15pm
424B3
t8bst n9wviwjo
11 Jul 23
Prospectus supplement
5:28pm
8-K
EX-99.1
wxn6neuw
28 Oct 22
CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues
5:15pm